Search 

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patientdriven platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees.

Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

Northern Biotechnologies has raised $1.5M in round "a" private funding. Northern is seeking commercialization and investment partnerships to continue the development of additional anti-bacterial, anti- viral and anti-fungal applications of our technology which require additional testing, proof of concept and commercialization partners.

Northern Biotechnologies is pioneering the commercialization of an innovative, long lasting, therapeutic anti-microbial technology that has significant applications in the Human Health Care arena. Infectious disease control and prevention

can be revolutionized by integration of our cost saving technology. Issued Patents and proprietary production IP offer a stable platform for growth and partnership into all human related applications of the technology. A unique feature of the technology is its extended protection of 1-3 days through each application. Additionally, the physical method of pathogen destruction prevents formation of resistant strain types, in contrast to existing technologies that rely on metabolic action for kill. Testing shows high performance anti-bacterial, anti-fungal and anti- viral functioning in various direct, topical, and wound care, nasal/ oral and related dosing mechanisms of the technology. We are in process with the first New Drug Application for antiseptic hand wash, and are looking for partners to pursue additional drug approvals in specific markets.

Existing product branding in the Human market is Prefense hand sanitizer and wipes. In addition to human applications, Northern holds over twenty-five global patents for anti-microbial water filtration using our technology. We also hold EPA registrations for persistent antimicrobial filter media. Significant opportunity exists in the technology used as a multi surface sanitizer for all levels of food production. Other existing product lines and cash flow are in place from additional internally developed technologies including high performance filtration medias, biotech remediation and process technologies used in petroleum, agricultural, and industrial processing. Northern also holds nationally placed consumer and professional brand lines of "green probiotic" cleaning products based on our IP and manufacturing base. Additionally, our cGMP contract packaging division sells our proprietary formulations to many national brands in a variety of markets. Company management is made of a diverse team with the experience and drive required to steer strong growth and relationships with partner companies.